BeOne Medicines Signs $2B Deal for Preclinical Trispecific Antibody Option with China's Huahui Health
BeOne Medicines is paying $20 million upfront to reserve the exclusive option to license HH160, a preclinical trispecific antibody developed by China's Huahui Health
If BeOne exercises the option, it will pay an additional $100 million licensing fee to acquire HH160
The total deal value reaches $2 billion when including potential milestone payments of up to $1.9 billion plus tiered royalties on future sales
HH160 was developed using Huahui's PolyBoost multispecific antibody platform and targets three immune checkpoints:
PD-1, CTLA-4, and VEGF-A
Preclinical data presented at the American Association for Cancer Research annual meeting suggested HH160 could harness synergistic anti-tumor mechanisms, overcome monotherapy resistance, and simplify dosing regimens
BeOne is also considering participation in Huahui's future financing rounds, to be negotiated separately
BeOne has previously advanced a trispecific antibody candidate, BG-T187 targeting EGFR and two c-Met epitopes, into a phase 1 clinical trial initiated in 2024